Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alden C Klarer

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Critical Reviews in Eukaryotic Gene Expression|December 21, 2011
Replication of damaged genomesAlden C Klarer, W McGregor
Oncotarget|August 14, 2014
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growthJason Chesney, Jennifer Clark, Alden C Klarer, et al.
Plos One|June 30, 2012
DNA polymerase eta participates in the mutagenic bypass of adducts induced by benzo[a]pyrene diol epoxide in mammalian cellsAlden C Klarer, L Jay Stallons, Tom J Burke, et al.
Journal of Translational Medicine|May 18, 2012
Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activationSucheta Telang, Brian F Clem, Alden C Klarer, et al.
Cancer & Metabolism|January 24, 2014
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanismAlden C Klarer, Julie O'Neal, Yoannis Imbert-Fernandez, et al.
Molecular Cancer|August 25, 2012
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growthSucheta Telang, Kristin K Nelson, Deanna L Siow, et al.
Molecular Cancer Therapeutics|May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancerBrian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
BMC Cancer|December 15, 2011
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanomaSucheta Telang, Mary Ann Rasku, Amy L Clem, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Critical Reviews in Eukaryotic Gene Expression|December 21, 2011
Replication of damaged genomesAlden C Klarer, W McGregor
Oncotarget|August 14, 2014
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growthJason Chesney, Jennifer Clark, Alden C Klarer, et al.
Plos One|June 30, 2012
DNA polymerase eta participates in the mutagenic bypass of adducts induced by benzo[a]pyrene diol epoxide in mammalian cellsAlden C Klarer, L Jay Stallons, Tom J Burke, et al.
Journal of Translational Medicine|May 18, 2012
Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activationSucheta Telang, Brian F Clem, Alden C Klarer, et al.
Cancer & Metabolism|January 24, 2014
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanismAlden C Klarer, Julie O'Neal, Yoannis Imbert-Fernandez, et al.
Molecular Cancer|August 25, 2012
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growthSucheta Telang, Kristin K Nelson, Deanna L Siow, et al.
Molecular Cancer Therapeutics|May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancerBrian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
BMC Cancer|December 15, 2011
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanomaSucheta Telang, Mary Ann Rasku, Amy L Clem, et al.
Pageof 1